CHEM2052 Tutorial Example4
From Proteopedia
(Difference between revisions)
| Line 13: | Line 13: | ||
== '''Active Site''' == | == '''Active Site''' == | ||
| - | This representation illustrates the <scene name='59/596437/Renin_catalytic_residues/2'>active site catalytic residues</scene> of Renin. Consider the mechanism of the enzymatic cleavage of the natural peptide substrate angiotensinase. Identify the structure of the transition state. In later lectures we will see how knowledge of the transition state can be used to design very effective enzyme inhibitors called "transition state" inhibitors. | + | This representation illustrates the <scene name='59/596437/Renin_catalytic_residues/2'>active site catalytic residues</scene> of Renin. Consider the mechanism of the enzymatic cleavage of the natural peptide substrate angiotensinase. Identify the structure of the transition state. In later lectures we will see how knowledge of the transition state can be used to design very effective enzyme inhibitors which mimic this transition state these are (not surprisingly) called "transition state" inhibitors. |
== '''Inhibition of Renin''' == | == '''Inhibition of Renin''' == | ||
Revision as of 07:40, 13 August 2014
CHEM2052_Tutorial_Example4
| |||||||||||
References
- ↑ Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ. Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5912-49. Epub 2007 Jun 2. PMID:17574423 doi:10.1016/j.bmc.2007.05.069

